We canβt show the full text here under this license. Use the link below to read it at the source.
Immunogenicity of fractional and standard dose COVID-19 vaccine boosters among healthy adults in Indonesia: twenty four month follow-up from a randomised controlled trial
Immune response to smaller and full COVID-19 vaccine booster doses in healthy adults in Indonesia over 24 months
AI simplified
Abstract
Of 1,289 trial participants, 962 (75%) completed follow-up to 24 months after receiving booster doses.
- Among participants initially vaccinated with CoronaVac, immune responses were lower with fractional doses of Pfizer compared to standard doses at 28 days.
- Differences in immune responses between fractional and standard doses diminished by 12 and 24 months.
- Participants primed with AstraZeneca demonstrated lower initial immune responses compared to those primed with CoronaVac after receiving Pfizer and AstraZeneca boosters.
- Breakthrough infections were reported in over 40% of participants between six and 12 months, and in over 35% between 12 and 24 months.
- Both fractional and standard doses of AstraZeneca and Pfizer boosted immune responses among participants primed with either CoronaVac or AstraZeneca.
AI simplified
Key numbers
3740 BAU/ml
Initial Immune Response ()
of binding antibodies in participants boosted with Pfizer fractional doses at 28 days.
>40%
Rate
Percentage of participants experiencing breakthrough infections between 6 and 12 months.
4969 BAU/ml
Antibody Response Comparison
of binding antibodies in participants boosted with Pfizer standard doses at 28 days.